HtmlToText
toggle navigation -- about us company overview management team project team board of directors stroke stroke in brief stroke outcomes stroke treatment a new target — gpvi our product partners & investors news & media press releases media coverage publications contact for a safe and effective treatment of stroke acticor biotech is a biopharmaceutical company, founded in 2013 as a spin-off of inserm (paris, france), developing an innovative drug for the treatment in the acute phase of ischemic stroke. according to the world health organization, 15 million people suffer stroke worldwide each year. of these, 6 million die and another 5 million are permanently disabled. stroke is the third cause of death in the world and the first cause of adult acquired disabilities resulting learn more on acticor biotech july 31, 2018 press releases a +60m€ regional development and commercialisation agreement signed with china medical system holding limited® paris, july 31, 2018 – acticor biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, announces the signature of an asset transfer and licensing agreement covering a development and commercialisation collaboration agreement with cms medical limited as well as an investment agreement with cms medical […] read more strong market potential unmeet market needs 15 million strokes in the world annually, 15 million first-ever strokes occur in the world. this number is due to increase because of aging population: in 1990 the world population over 60 years old was 488 millions, in 2030 the projected number is 1,363 millions. learn more 3rd cause of death stroke is the 3rd cause of death in industrialized countries (6 million deaths worldwide). the second cause of dementia after alzheimer's disease and the leading cause of acquired disability in adults. in france, the annual incidence of stroke is estimated at 140,000 cases. learn more major economic impact in addition to being a major public health issue, stroke has a tremendous economic impact. for instance, in 2010 stroke-related medical costs and disability cost about 34 billion dollars to the usa. in the eu countries, the total annual cost of stroke is estimated at 38 billion euros, including the value of informal care. learn more our aim : a drug candidate with unique benefits unmeet medical needs in acute stroke despite some health and economic needs, no pharmaceutical treatment is currently satisfactory for the treatment of stroke. thus, fewer than 10% of patients can be treated with thrombolysis, only effective in the first 4.5h (as approved in eu, 3h in usa) of a stroke, and no existing antiplatelet drugs are suitable for the treatment of acute stroke because of their bleeding risk. a first-in class antithrombotic agent our drug candidate is an antithrombotic agent, designed to reduce the size of the clot, prevent recurrences without bleeding risk and is intended to be used within the first 12 hours. no bleeding risk the drug is directed against a novel target of major interest, platelet glycoprotein vi (gpvi) and inhibits its action. evidence of antithrombotic efficacy and safety of inhibition of gpvi has been established ex vivo but also in in vivo models. the target is involved in the growth of the thrombus and not in physiological hemostasis making the drug candidate the first antithrombotic without bleeding risk. news & media july 31, 2018 press releases a +60m€ regional development and commercialisation agreement signed with china medical system holding limited® paris, july 31, 2018 – acticor biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, announces the signature of an asset transfer and licensing agreement covering a development and commercialisation collaboration agreement with cms medical limited as well as an investment agreement with cms medical […] read more june 14, 2018 press releases acticor biotech confirms simbec-orion to make its first in patient study in acute ischemic stroke paris, june 14, 2018 – acticor biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, as part of the development of its first drug candidate act017 who has just successfully completed a phase 1 study in the healthy volunteer, confided to simbec-orion carrying out his […] read more april 26, 2018 publications quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: a case study prior to pharmaceutical development quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: a case study prior to pharmaceutical development in new biotechnology, 2018 authors kristell lebozec, martine jandrot-perrus, gilles avenard, olivier favre-bulle, and philippe billiald. abstract monoclonal antibody fragments (fab) are a promising class of therapeutic agents. fabs are aglycosylated […] read more main navigation about us stroke our product press releases media coverage publications investors contact contact us follow us on twitter follow us on linkedin acticor biotech bâtiment inserm u1148 hôpital bichat, secteur claude bernard 46 rue henri huchard 75877 paris cedex 18 © 2018 acticor biotech sas. legal mentions . credits .
Informations Whois
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
Domain Name: ACTICOR-BIOTECH.COM
Registry Domain ID: 1811289262_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.1and1.com
Registrar URL: http://registrar.1and1.info
Updated Date: 2017-06-28T07:24:52Z
Creation Date: 2013-06-27T16:10:46Z
Registry Expiry Date: 2018-06-27T16:10:46Z
Registrar: 1&1 Internet SE
Registrar IANA ID: 83
Registrar Abuse Contact Email: abuse@1and1.com
Registrar Abuse Contact Phone: +1.6105601459
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS-FR.1AND1-DNS.BIZ
Name Server: NS-FR.1AND1-DNS.COM
Name Server: NS-FR.1AND1-DNS.FR
Name Server: NS-FR.1AND1-DNS.ORG
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-08-23T13:21:38Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
REGISTRAR 1&1 Internet SE
SERVERS
SERVER com.whois-servers.net
ARGS domain =acticor-biotech.com
PORT 43
TYPE domain
RegrInfo
DOMAIN
NAME acticor-biotech.com
CHANGED 2017-06-28
CREATED 2013-06-27
STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
NSERVER
NS-FR.1AND1-DNS.BIZ 217.160.81.4
NS-FR.1AND1-DNS.COM 217.160.82.4
NS-FR.1AND1-DNS.FR 217.160.80.4
NS-FR.1AND1-DNS.ORG 217.160.83.4
REGISTERED yes
Go to top
acticor-biotech.com rapport :
Visitez le site